<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "JATS-journalpublishing1-4.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.4" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ijoc</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Organic Chemistry</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2161-4695</issn>
      <issn pub-type="ppub">2161-4687</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/ijoc.2026.163007</article-id>
      <article-id pub-id-type="publisher-id">ijoc-153720</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
        <subj-group>
          <subject>Biomedical</subject>
          <subject>Life Sciences</subject>
          <subject>Chemistry</subject>
          <subject>Materials Science</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Organic Reactions between Therapeutic Compounds and Pathogenic Microorganism Cellular Chemical Components</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0004-7588-2084</contrib-id>
          <name name-style="western">
            <surname>Mwene-Mbeja</surname>
            <given-names>Topwe Milongwe</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Department of Chemistry, Faculty of Science, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo </aff>
      <aff id="aff2"><label>2</label> Hydro-Quebec Institute for Environment, Development and Society, Laval University, Quebec, Canada </aff>
      <aff id="aff3"><label>3</label> Research Center on Water Management and Environment (CREE), Kinshasa, Democratic Republic of the Congo </aff>
      <author-notes>
        <fn fn-type="conflict" id="fn-conflict">
          <p>The author declares no conflicts of interest regarding the publication of this paper.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>09</month>
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>09</month>
        <year>2026</year>
      </pub-date>
      <volume>16</volume>
      <issue>03</issue>
      <fpage>124</fpage>
      <lpage>149</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>05</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>09</month>
          <year>2026</year>
        </date>
        <date date-type="published">
          <day>09</day>
          <month>09</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2026 by the authors and Scientific Research Publishing Inc.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <license license-type="open-access">
          <license-p> This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> ). </license-p>
        </license>
      </permissions>
      <self-uri content-type="doi" xlink:href="https://doi.org/10.4236/ijoc.2026.163007">https://doi.org/10.4236/ijoc.2026.163007</self-uri>
      <abstract>
        <p>The biological properties of therapeutic compounds to degrade pathogenic microorganisms have been explained from organic chemistry perspective. Precisely, this paper has properly shown the mode of action concerning acidic therapeutic compounds possessing hydroxyl or carboxylic groups including alkaloid therapeutic compounds bearing a nitrogen atom or an amine group. In other words, this conceptual research has disclosed detailed reaction mechanisms, which demonstrate how an adequate medicine can neutralize or degrade one of the essential microbial cellular chemical constituents, such as the deoxyribonucleic acid (DNA).</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated" xml:lang="en">
        <kwd>Therapeutic Compounds</kwd>
        <kwd>Reaction Mechanisms</kwd>
        <kwd>Glycoproteins</kwd>
        <kwd>Glucolipids</kwd>
        <kwd>Phospholipids</kwd>
        <kwd>Deoxyribonucleic Acid (DNA)</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <sec id="sec1dot1">
        <title>1.1. Glycoprotein</title>
        <p>A glycoprotein is an organic compound bearing a glycosyl motif bound to a proteinic portion. It is found in all cells of the leaving organisms such as animals, bacteria, virus, and plants [<xref ref-type="bibr" rid="B1">1</xref>]. It reacts with nucleophilic extracellular substances such as medicines to assist them to penetrate the intracellular environment (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
      </sec>
      <sec id="sec1dot2">
        <title>1.2. Glycolipid</title>
        <p>A glycolipid is one of the cellular membrane organic compounds functioning as a receptor of the adequate extracellular chemical substances, which intend to pass through the cellular membrane [<xref ref-type="bibr" rid="B1">1</xref>]. It is a combination of a glycosyl residue connected to a third carbon atom of a glycerol moisty, at which the first and the second carbon atoms are respectively attached to a fatty acid molecule (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
        <fig id="fig1">
          <label>Figure 1</label>
          <graphic xlink:href="https://html.scirp.org/file/1020901-rId17.jpeg?20260909101048" />
        </fig>
        <p><bold>Figure 1.</bold>Glycoprotein definition.</p>
        <fig id="fig2">
          <label>Figure 2</label>
          <graphic xlink:href="https://html.scirp.org/file/1020901-rId18.jpeg?20260909101048" />
        </fig>
        <p><bold>Figure 2.</bold>Glycolipid definition.</p>
      </sec>
      <sec id="sec1dot3">
        <title>1.3. Phospholipid</title>
        <p>A phospholipid is a cellular membrane component, which is an organic substance formed by a glycerol residue, a phosphate group and two fatty acids [<xref ref-type="bibr" rid="B1">1</xref>]. Indeed, the two fatty acids are bound to the first and to the second glycerol carbon atom, while the third glycerol carbon atom bears the phosphate group. It is also an appropriate cellular receptor for nucleophilic extracellular substances, which cross the cellular membrane in order to reach the cellular cytoplasm (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
        <fig id="fig3">
          <label>Figure 3</label>
          <graphic xlink:href="https://html.scirp.org/file/1020901-rId19.jpeg?20260909101051" />
        </fig>
        <p><bold>Figure 3.</bold>Phospholipid definition.</p>
      </sec>
      <sec id="sec1dot4">
        <title>1.4. Therapeutic Organic Compounds</title>
        <p>Therapeutic organic compounds are natural or synthetic organic substances susceptible to destroy or inhibit pathogen microorganisms by preventing their development. Indeed, I have read the literature regarding therapeutic organic compounds towards pathogenic microorganisms, and I have found that their action mechanisms do not properly taking account the organic reactions. To alleviate this type of insufficient, I have proposed organic reaction mechanisms, which constitute an added value to enhance the comprehension of the biological activities of pharmaceutical substances in comparison to those already published that do not disclose the advanced organic reactions involving healing compounds et pathogenic microorganism cellular constituents such as glycoproteins, glycolipids as well as phospholipids [<xref ref-type="bibr" rid="B2">2</xref>]-[<xref ref-type="bibr" rid="B7">7</xref>]. It is important to herein remind that this paper aims to demonstrate detailed reaction mechanism in order to elucidate the neutralization of the essential microbial cellular chemical constituents, such as proteins, phospholipids, glucolipids or deoxyribonucleic acid (DNA). In the same perspective, therapeutic compounds studied into this conceptual paper have been selected in respect to their categories containing functional groups such as hydroxyl, amine and carboxylic group.</p>
      </sec>
    </sec>
    <sec id="sec2">
      <title>2. Dipeptide Boronic Acid</title>
      <p>Dipeptide boronic acid, known as bortezomib, is an organic therapeutic compound containing functional groups that are capable to donate protons to nucleophiles or bases [<xref ref-type="bibr" rid="B8">8</xref>]-[<xref ref-type="bibr" rid="B11">11</xref>]. This therapeutic compound neutralizes pathogen organisms because it has been designed to react mainly with microbial proteinase or an enzyme which accelerates the destruction of microbial proteins, which are essential for the pathogen organism development [<xref ref-type="bibr" rid="B8">8</xref>]-[<xref ref-type="bibr" rid="B11">11</xref>]. Regarding the mechanism of action of the therapeutic compound, this later will donate protons to proteinase to yield the corresponding products (<bold>Scheme 1</bold>, reaction 2). Then a molecule of water will finalize the deterioration of the targeted proteinase (<bold>Scheme 1</bold>, reaction 3). It has been reported that histidine, serine and aspartic acid residues constitute a catalytic region of serine proteinase [<xref ref-type="bibr" rid="B12">12</xref>].</p>
    </sec>
    <sec id="sec3">
      <title>3. Berberine</title>
      <p>This therapeutic compound has medicinal properties against diarrhea, microbial pathogens as well as gastrointestinal suffering [<xref ref-type="bibr" rid="B13">13</xref>]. The structure of this compound shows functional groups where organic reactions can take place. Indeed, the proposed reaction mechanism, plausibly explains the reaction between berberine hydroxyl group and the phospholipid of the pathogenic organism cellular membrane, is that a phosphate group of phospholipid accepts a proton of the berberine hydroxyl group to generate a conjugate base of berberine and the protonated phospholipid (<bold>Scheme 2</bold>, reaction 1). This step is followed by two substitution reactions due to nucleophilic addition of two equivalents (eq.) of berberine conjugate base towards two fatty acid substituents of the protonated phospholipid, and the same conjugate base will reaction with the resulting phosphoglycerate to displace a corresponding leaving group (<bold>Scheme 2</bold>, reaction 2, reaction 3).</p>
      <p>When the berberine analogue has reached the cellular cytoplasm, the parent </p>
      <fig id="fig4">
        <label>Figure 4</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId20.jpeg?20260909101056" />
      </fig>
      <fig id="fig5">
        <label>Figure 5</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId21.jpeg?20260909101056" />
      </fig>
      <fig id="fig6">
        <label>Figure 6</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId22.jpeg?20260909101056" />
      </fig>
      <p><bold>Scheme 1.</bold> Dipeptide boronic acid chemistry.</p>
      <fig id="fig7">
        <label>Figure 7</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId23.jpeg?20260909101056" />
      </fig>
      <fig id="fig8">
        <label>Figure 8</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId24.jpeg?20260909101056" />
      </fig>
      <p><bold>Scheme 2.</bold> Berberine chemistry.</p>
      <p>compound or the original one will be regenerated as well as the phospholipid to allow berberine to destroy or react with deoxyribonucleic acid (DNA). Consequently, the targeted pathogenic organism can no longer survive (<bold>Scheme 3</bold>, reaction 5).</p>
      <p>Berberine can be regenerated through the reaction between the intermediate berberine phosphate and the appropriate nucleophile (<bold>Scheme 4</bold>).</p>
      <p>Experimental studies have revealed that in acid environment, the structure of berberine possesses quaternary nitrogen resulting from the displacement of a molecule of water because berberine reacts with mineral acids such as hydrogen chloride or sulfuric acid (<bold>Scheme 5</bold>) [<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <fig id="fig9">
        <label>Figure 9</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId25.jpeg?20260909101057" />
      </fig>
      <fig id="fig10">
        <label>Figure 10</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId26.jpeg?20260909101057" />
      </fig>
      <p><bold>Scheme 3.</bold> Berberine analogue chemistry.</p>
      <fig id="fig11">
        <label>Figure 11</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId27.jpeg?20260909101056" />
      </fig>
      <p><bold>Scheme 4.</bold> Berberine regeneration.</p>
      <fig id="fig12">
        <label>Figure 12</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId28.jpeg?20260909101056" />
      </fig>
      <p><bold>Scheme 5.</bold> Acid environment berberine chemistry.</p>
    </sec>
    <sec id="sec4">
      <title>4. Ephedrine</title>
      <p>This pharmaceutical compound is an alkaloid containing an amine functional group where an interesting reaction towards the targeted microbe occurs. This therapeutic compound utilizes the electron density around an intrinsic nitrogen atom to react with the cellular membrane glycoproteins. The plausible reaction mechanism starts with the disintegration of the glycoprotein due to an electron lone pair, on the intra oxygen, to generate a cyclic oxocarbonium ion, which is an excellent electrophile or more reactive than the entire glycoprotein due to its chair-like conformation. This conformation des not align the electron lone pair on the intra oxygen antiperiplanarly to the leaving group (<bold>Scheme 6</bold>, reaction 1) [<xref ref-type="bibr" rid="B15">15</xref>]. This step is followed by the nucleophilic addition of an electron lone pair of the nitrogen atom to produce the corresponding ammonium compound, which gives a proton to an adequate nucleophile to furnish the glycoprotein analogue, which can diffuse or migrate through the cellular membrane up to the cellular cytoplasm (<bold>Scheme 6</bold>, reaction 2, reaction 3).</p>
      <fig id="fig13">
        <label>Figure 13</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId29.jpeg?20260909101058" />
      </fig>
      <p><bold>Scheme 6.</bold> Ephedrine alkaloid chemical properties.</p>
      <p>Within the cellular cytoplasm, the ephedrine analogue will react with the nucleophilic reactive entity to regenerate glycoprotein and the therapeutic original ephedrine that will now react with the deoxyribonucleic acid (DNA) (<bold>Scheme 7</bold>).</p>
      <fig id="fig14">
        <label>Figure 14</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId30.jpeg?20260909101059" />
      </fig>
      <p><bold>Scheme 7.</bold> Ephedrine analogue chemistry.</p>
    </sec>
    <sec id="sec5">
      <title>5. Aspirin</title>
      <p>Experimental observations have disclosed that aspirin has diverse medicinal properties particularly anticancer, anti cholesterol, antibacterial dissemination including anti-inflammatory properties [<xref ref-type="bibr" rid="B16">16</xref>]-[<xref ref-type="bibr" rid="B19">19</xref>]. The structure of this therapeutic compound shows a carboxylic function group, which can react with glycolipid to furnish the corresponding products. This kind of reaction implies the protonation of the glycolipid to generate the corresponding products (<bold>Scheme 8</bold>, reaction 1). This step is followed by the electron lone pair delocalisation in order to displace the leaving group along with the carbo-oxonium ion (<bold>Scheme 8</bold>, reaction 2). In the third step, the aspirin conjugate base will combine with the carbo-oxonium ion to produce the corresponding aspirin analogue or glycolipid analogue because of a glycoside group bearing amide moisture is attached to aspirin (<bold>Scheme 8</bold>, reaction 3). Consequently, the aspirin analogue can now easily move through the cellular membrane to reach the pathogenic microorganism cytoplasm where the aspirin will be regenerated before reacting or neutralizing the pathogenic microorganism DNA in order to inhibit its development (<bold>Scheme 8</bold>, reaction 7). The glycolipid will be regenerated as well (<bold>Scheme 8</bold>, reaction 6).</p>
    </sec>
    <sec id="sec6">
      <title>6. Scientific Literature</title>
      <p>The proposed explanation model regarding the interactions between therapeutic compounds, and the pathogenic microorganism principal chemical components is essentially supported by experimental observations found in the scientific literature. Indeed, il has been reported that the medicines interact straight with the cellular membrane, and this kind of interaction is still disregarded [<xref ref-type="bibr" rid="B20">20</xref>][<xref ref-type="bibr" rid="B21">21</xref>]. In the same perspective, it has also been reported that healing organic compounds react with cellular membrane chemical constituents so as they can pass through the cellular membrane to reach the cytoplasm [<xref ref-type="bibr" rid="B20">20</xref>][<xref ref-type="bibr" rid="B21">21</xref>]. In other words, the capability of therapeutic compounds to react with the cellular membrane chemical constituents remains one of the significant therapeutic characteristic, which plays a fundamental role into their bioactive properties [<xref ref-type="bibr" rid="B20">20</xref>][<xref ref-type="bibr" rid="B21">21</xref>]. In the same situation, Authors have found specifically during the experimental observations that rifampicin and levofloxacin react with the lipid phosphate group (<bold>Scheme 9</bold>, reaction 2) as well as the carbonyl group of lipids (<bold>Scheme 9</bold>, reaction 4) [<xref ref-type="bibr" rid="B22">22</xref>].</p>
      <p>The plausible reaction mechanism for rifampicin and levofloxacin is due to their structure because the structure of an organic compound determines its reactivity. Accordingly, rifampicin can use its functional polar groups to interact with phosphate group (<bold>Scheme 9</bold>, reaction 2) or carbonyl group (<bold>Scheme 9</bold>, reaction 4) of the cellular membrane lipids, as nucleophiles in order to cross the cellular membrane and so to reach the cytoplasm [<xref ref-type="bibr" rid="B23">23</xref>]. Indeed, according to the electronegativity, the hydroxyl group oxygen atom is more electronegative than the nitrogen atom into the piperazine group, which is present into these two therapeutic compounds (<bold>Scheme 9</bold>). Therefore, the nitrogen atom behaves better as nucleophile than the oxygen atom because the nitrogen atom can easily concede its free double electrons to an electrophile such as a phosphate group to generate an analogue to phospholipid or the rifampicin bearing a phosphate group (<bold>Scheme 9</bold>, reaction 2). In the same perspective, it has been reported that glutamate, and phenylalanine play a fundamental role into the active site of ATPase (adenosine triphosphate enzyme) (<bold>Scheme 9</bold>, reaction 1), an enzyme which facilitates the </p>
      <fig id="fig15">
        <label>Figure 15</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId31.jpeg?20260909101104" />
      </fig>
      <fig id="fig16">
        <label>Figure 16</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId32.jpeg?20260909101104" />
      </fig>
      <fig id="fig17">
        <label>Figure 17</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId33.jpeg?20260909101104" />
      </fig>
      <p><bold>Scheme 8.</bold> Aspirin chemistry.</p>
      <fig id="fig18">
        <label>Figure 18</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId34.jpeg?20260909101105" />
      </fig>
      <fig id="fig19">
        <label>Figure 19</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId35.jpeg?20260909101104" />
      </fig>
      <p><bold>Scheme 9.</bold> Rifampicin reaction mechanism.</p>
      <p>extracellular therapeutic substances to cross the cellular membrane [<xref ref-type="bibr" rid="B23">23</xref>]-[<xref ref-type="bibr" rid="B26">26</xref>].</p>
      <p>Due to the presence of a phosphate group or a fatty acid group, rifampicin can easily cross the cellular membrane to penetrate the cytoplasm area of a cell, where it will be released by reacting with the nucleophilic conjugate base of the phospholipid because these biochemical reactions are reversible (<bold>Scheme 10</bold>, reactions 1-2). Then the free rifampicin will react with the microorganism deoxyribonucleic acid (DNA) to destroy the pathogenic agent (<bold>Scheme 10</bold>, reaction 3).</p>
      <fig id="fig20">
        <label>Figure 20</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId36.jpeg?20260909101105" />
      </fig>
      <fig id="fig21">
        <label>Figure 21</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId37.jpeg?20260909101105" />
      </fig>
      <p><bold>Scheme 10.</bold>Rifampicin reaction mechanism of DNA degradation.</p>
      <p>The interaction of levofloxacin with the phospholipid phosphate group or with the carbonyl group of the phospholipid follows the same pathway as the stated above for rifampicin. In other words, levofloxacin will use its nitrogen atom into the piperazine group to react with the electrophilic phosphate group as well as the electrophilic carbonyl group of the appropriate phospholipid to produce the corresponding intermediate derivative, and its penetration into the cellular cytoplasm will be guided by the presence on it of the phosphate group (<bold>Scheme 11</bold>, reaction 1) as well as the presence of the acyl group (<bold>Scheme 11</bold>, reaction 2).</p>
      <p>It is important to mention that organic compounds, which constitute the cellular membrane and organic compounds into the cellular cytoplasm are both into the same cellular reaction medium. Consequently, the levofloxacin bearing a phosphate group will react with the phospholipid conjugate base to regenerate </p>
      <fig id="fig22">
        <label>Figure 22</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId38.jpeg?20260909101104" />
      </fig>
      <p><bold>Scheme 11</bold><bold>.</bold>Levofloxacin reaction mechanism.</p>
      <p>the phospholipid and the levofloxacin (<bold>Scheme 12</bold>, reaction 1). In the same context, the levofloxacin bearing an acyl group will react with the second phospholipid conjugate base to regenerate phospholipid and the levofloxacin (<bold>Scheme 12</bold>, reaction 2). Being free or regenerated into the cellular cytoplasm, the levofloxacin medicine can now neutralize the microorganism DNA by utilizing its nucleophilic character to donate electrons to the microorganism DNA electrophile (<bold>Scheme 12</bold>, reaction 3).</p>
      <p>Being that the cellular cytoplasm is an aqueous reaction medium, a molecule of water can hydrolyze the resulting products to regenerate an entire therapeutic compound (<bold>Scheme 13</bold>).</p>
      <p>It has also been reported that levodopa is a promedicine of dopamine, and it is used to treat Parkinson disease. Being very polar organic compound, the dopamine is not administrated as such, but it is administrated as levodopa because this later is an amino acid susceptible to be recognized by a specific cellular receptor such as glycoprotein, which will facilitate it to pass through the cellular membrane [<xref ref-type="bibr" rid="B27">27</xref>][<xref ref-type="bibr" rid="B28">28</xref>]. When levodopa is now into the cytoplasm, decarboxylase enzyme </p>
      <fig id="fig23">
        <label>Figure 23</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId39.jpeg?20260909101104" />
      </fig>
      <p><bold>Scheme 12.</bold>Levofloxacin reaction mechanism of DNA degradation.</p>
      <fig id="fig24">
        <label>Figure 24</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId40.jpeg?20260909101103" />
      </fig>
      <p><bold>Scheme 13.</bold> Levofloxacin regeneration.</p>
      <p>will catalyze the cleavage of its carboxylic group, and the dopamine is thus released within the cell. It is important to mention that serine and aspartate residues play a fundamental catalytic role into the decarboxylase enzyme active site (<bold>Scheme 14</bold>, reaction 1).</p>
      <fig id="fig25">
        <label>Figure 25</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId41.jpeg?20260909101103" />
      </fig>
      <fig id="fig26">
        <label>Figure 26</label>
        <graphic xlink:href="https://html.scirp.org/file/1020901-rId42.jpeg?20260909101103" />
      </fig>
      <p><bold>Scheme 14.</bold> Pro medicine chemistry.</p>
    </sec>
    <sec id="sec7">
      <title>7. Conclusion</title>
      <p>I have comprehensibly explained the degradation of pathogenic microorganisms by adequate therapeutic compounds using advanced organic reactions. Indeed, therapeutic compounds chosen into this conceptual study have been selected according to their chemical behavior due to their characteristic functional groups where organic reactions take place. It is noteworthy to mention that the selected therapeutic compounds can react as acids, bases, nucleophiles or electrophiles with microorganism glycoproteins, phospholipids, glycolipids or deoxyribonucleic acid (DNA). In other words, the biological activity of this kind of therapeutic organic compounds has been demonstrated in detailed fashion using reaction mechanism stage by stage up to the neutralization of the targeted pathogenic microorganisms and in that context, to support this conceptual study, scientific experimental observations regarding the reactivity of some medicines such as rifampicin and levofloxacin have been found that they react with the cellular membrane constituents before entering the intracellular environment.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Mwene-Mbeja, T.M. (2026) Applied Research: Conceptual Study of Cellular Membrane Organic Compounds Enzymatic Synthesis towards Promedicine of Dopamine and Cocaine Penetration into the Cytoplasm. <italic>Open Acces</italic><italic>s</italic><italic>Journal of Chemistry</italic>, 8, 50-73. https://doi.org/10.22259/2637-5834.0801003 <pub-id pub-id-type="doi">10.22259/2637-5834.0801003</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.22259/2637-5834.0801003">https://doi.org/10.22259/2637-5834.0801003</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Mwene-Mbeja, T.M.</string-name>
            </person-group>
            <year>2026</year>
            <article-title>Applied Research: Conceptual Study of Cellular Membrane Organic Compounds Enzymatic Synthesis towards Promedicine of Dopamine and Cocaine Penetration into the Cytoplasm</article-title>
            <source>Open Access Journal of Chemistry</source>
            <volume>8</volume>
            <pub-id pub-id-type="doi">10.22259/2637-5834.0801003</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Mickymaray, S. (2019) Efficacy and Mechanism of Traditional Medicinal Plants and Bioactive Compounds against Clinically Important Pathogens. <italic>Antibiotics</italic>, 8, Article 257. https://doi.org/10.3390/antibiotics8040257 <pub-id pub-id-type="doi">10.3390/antibiotics8040257</pub-id><pub-id pub-id-type="pmid">31835403</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/antibiotics8040257">https://doi.org/10.3390/antibiotics8040257</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Mickymaray, S.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Efficacy and Mechanism of Traditional Medicinal Plants and Bioactive Compounds against Clinically Important Pathogens</article-title>
            <source>Antibiotics</source>
            <volume>8</volume>
            <elocation-id>257</elocation-id>
            <pub-id pub-id-type="doi">10.3390/antibiotics8040257</pub-id>
            <pub-id pub-id-type="pmid">31835403</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Cruz, J., Ortiz, C., Guzmán, F., Fernández-Lafuente, R. and Torres, R. (2014) Antimicrobial Peptides: Promising Compounds against Pathogenic Microorganisms. <italic>Current Medicinal Chemistry</italic>, 21, 2299-2321. https://doi.org/10.2174/0929867321666140217110155 <pub-id pub-id-type="doi">10.2174/0929867321666140217110155</pub-id><pub-id pub-id-type="pmid">24533812</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/0929867321666140217110155">https://doi.org/10.2174/0929867321666140217110155</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Cruz, J.</string-name>
              <string-name>Ortiz, C.</string-name>
              <string-name>Lafuente, R.</string-name>
              <string-name>Torres, R.</string-name>
            </person-group>
            <year>2014</year>
            <article-title>Antimicrobial Peptides: Promising Compounds against Pathogenic Microorganisms</article-title>
            <source>Current Medicinal Chemistry</source>
            <volume>21</volume>
            <pub-id pub-id-type="doi">10.2174/0929867321666140217110155</pub-id>
            <pub-id pub-id-type="pmid">24533812</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Riaz, M., Khalid, R., Afzal, M., Anjum, F., Fatima, H., Zia, S., <italic>et al</italic>. (2023) Phytobioactive Compounds as Therapeutic Agents for Human Diseases: A Review. <italic>Food Science &amp; Nutrition</italic>, 11, 2500-2529. https://doi.org/10.1002/fsn3.3308 <pub-id pub-id-type="doi">10.1002/fsn3.3308</pub-id><pub-id pub-id-type="pmid">37324906</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/fsn3.3308">https://doi.org/10.1002/fsn3.3308</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Riaz, M.</string-name>
              <string-name>Khalid, R.</string-name>
              <string-name>Afzal, M.</string-name>
              <string-name>Anjum, F.</string-name>
              <string-name>Fatima, H.</string-name>
              <string-name>Zia, S.</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Phytobioactive Compounds as Therapeutic Agents for Human Diseases: A Review</article-title>
            <source>Food Science &amp; Nutrition</source>
            <volume>11</volume>
            <pub-id pub-id-type="doi">10.1002/fsn3.3308</pub-id>
            <pub-id pub-id-type="pmid">37324906</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Amaning Danquah, C., Minkah, P.A.B., Osei Duah Junior, I., Amankwah, K.B. and Somuah, S.O. (2022) Antimicrobial Compounds from Microorganisms. <italic>Antibiotics</italic>, 11, Article 285. https://doi.org/10.3390/antibiotics11030285 <pub-id pub-id-type="doi">10.3390/antibiotics11030285</pub-id><pub-id pub-id-type="pmid">35326749</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/antibiotics11030285">https://doi.org/10.3390/antibiotics11030285</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Danquah, C.</string-name>
              <string-name>Minkah, P.A.B.</string-name>
              <string-name>Junior, I.</string-name>
              <string-name>Amankwah, K.B.</string-name>
              <string-name>Somuah, S.O.</string-name>
            </person-group>
            <year>2022</year>
            <article-title>Antimicrobial Compounds from Microorganisms</article-title>
            <source>Antibiotics</source>
            <volume>11</volume>
            <elocation-id>285</elocation-id>
            <pub-id pub-id-type="doi">10.3390/antibiotics11030285</pub-id>
            <pub-id pub-id-type="pmid">35326749</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Basalla, J., Chatterjee, P., Burgess, E., Khan, M., Verbrugge, E., Wiegmann, D.D., <italic>et</italic><italic>al</italic>. (2019) Loci Encoding Compounds Potentially Active against Drug-Resistant Pathogens Amidst a Decreasing Pool of Novel Antibiotics. <italic>Applied and Environmental Microbiology</italic>, 85, e01438. https://doi.org/10.1128/aem.01438-19 <pub-id pub-id-type="doi">10.1128/aem.01438-19</pub-id><pub-id pub-id-type="pmid">31540982</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/aem.01438-19">https://doi.org/10.1128/aem.01438-19</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Basalla, J.</string-name>
              <string-name>Chatterjee, P.</string-name>
              <string-name>Burgess, E.</string-name>
              <string-name>Khan, M.</string-name>
              <string-name>Verbrugge, E.</string-name>
              <string-name>Wiegmann, D.D.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Loci Encoding Compounds Potentially Active against Drug-Resistant Pathogens Amidst a Decreasing Pool of Novel Antibiotics</article-title>
            <source>Applied and Environmental Microbiology</source>
            <volume>85</volume>
            <pub-id pub-id-type="doi">10.1128/aem.01438-19</pub-id>
            <pub-id pub-id-type="pmid">31540982</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Tiash, S., Saunders, J., Hart, C.J.S., Ryan, J.H., Riches, A.G. and Skinner-Adams, T.S. (2020) An Image-Based Pathogen Box Screen Identifies New Compounds with Anti-Giardia Activity and Highlights the Importance of Assay Choice in Phenotypic Drug Discovery. <italic>International Journal for Parasitology</italic>: <italic>Drugs and Drug Resistance</italic>, 12, 60-67. https://doi.org/10.1016/j.ijpddr.2020.03.002 <pub-id pub-id-type="doi">10.1016/j.ijpddr.2020.03.002</pub-id><pub-id pub-id-type="pmid">32234669</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijpddr.2020.03.002">https://doi.org/10.1016/j.ijpddr.2020.03.002</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Tiash, S.</string-name>
              <string-name>Saunders, J.</string-name>
              <string-name>Hart, C.J.S.</string-name>
              <string-name>Ryan, J.H.</string-name>
              <string-name>Riches, A.G.</string-name>
              <string-name>Skinner-Adams, T.S.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>An Image-Based Pathogen Box Screen Identifies New Compounds with Anti-Giardia Activity and Highlights the Importance of Assay Choice in Phenotypic Drug Discovery</article-title>
            <source>International Journal for Parasitology: Drugs and Drug Resistance</source>
            <volume>12</volume>
            <pub-id pub-id-type="doi">10.1016/j.ijpddr.2020.03.002</pub-id>
            <pub-id pub-id-type="pmid">32234669</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Voorhees, P.M., Dees, E.C., O’Neil, B. and Orlowski, R.Z. (2003) The Proteasome as a Target for Cancer Therapy. <italic>Clinical Cancer Research</italic>, 9, 6316-6325.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Voorhees, P.M.</string-name>
              <string-name>Dees, E.C.</string-name>
              <string-name>Neil, B.</string-name>
              <string-name>Orlowski, R.Z.</string-name>
            </person-group>
            <year>2003</year>
            <article-title>The Proteasome as a Target for Cancer Therapy</article-title>
            <source>Clinical Cancer Research</source>
            <volume>9</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Momose, I. and Kawada, M. (2016) The Therapeutic Potential of Microbial Proteasome Inhibitors. <italic>International</italic><italic>Immunopharmacology</italic>, 37, 23-30. https://doi.org/10.1016/j.intimp.2015.11.013 <pub-id pub-id-type="doi">10.1016/j.intimp.2015.11.013</pub-id><pub-id pub-id-type="pmid">26589840</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.intimp.2015.11.013">https://doi.org/10.1016/j.intimp.2015.11.013</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Momose, I.</string-name>
              <string-name>Kawada, M.</string-name>
            </person-group>
            <year>2016</year>
            <article-title>The Therapeutic Potential of Microbial Proteasome Inhibitors</article-title>
            <source>International Immunopharmacology</source>
            <volume>37</volume>
            <pub-id pub-id-type="doi">10.1016/j.intimp.2015.11.013</pub-id>
            <pub-id pub-id-type="pmid">26589840</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Moreira, W., Santhanakrishnan, S., Dymock, B.W. and Dick, T. (2017) Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome. <italic>Frontiers in Microbiology</italic>, 8, Article 746. https://doi.org/10.3389/fmicb.2017.00746 <pub-id pub-id-type="doi">10.3389/fmicb.2017.00746</pub-id><pub-id pub-id-type="pmid">28496439</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2017.00746">https://doi.org/10.3389/fmicb.2017.00746</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Moreira, W.</string-name>
              <string-name>Santhanakrishnan, S.</string-name>
              <string-name>Dymock, B.W.</string-name>
              <string-name>Dick, T.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome</article-title>
            <source>Frontiers in Microbiology</source>
            <volume>8</volume>
            <elocation-id>746</elocation-id>
            <pub-id pub-id-type="doi">10.3389/fmicb.2017.00746</pub-id>
            <pub-id pub-id-type="pmid">28496439</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Sogbein, O., Paul, P., Umar, M., Chaari, A., Batuman, V. and Upadhyay, R. (2024) Bortezomib in Cancer Therapy: Mechanisms, Side Effects, and Future Proteasome Inhibitors. <italic>Life Sciences</italic>, 358, Article 123125. https://doi.org/10.1016/j.lfs.2024.123125 <pub-id pub-id-type="doi">10.1016/j.lfs.2024.123125</pub-id><pub-id pub-id-type="pmid">39413903</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lfs.2024.123125">https://doi.org/10.1016/j.lfs.2024.123125</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Sogbein, O.</string-name>
              <string-name>Paul, P.</string-name>
              <string-name>Umar, M.</string-name>
              <string-name>Chaari, A.</string-name>
              <string-name>Batuman, V.</string-name>
              <string-name>Upadhyay, R.</string-name>
              <string-name>Mechanisms, S</string-name>
            </person-group>
            <year>2024</year>
            <article-title>Bortezomib in Cancer Therapy: Mechanisms, Side Effects, and Future Proteasome Inhibitors</article-title>
            <source>Life Sciences</source>
            <volume>358</volume>
            <elocation-id>123125</elocation-id>
            <pub-id pub-id-type="doi">10.1016/j.lfs.2024.123125</pub-id>
            <pub-id pub-id-type="pmid">39413903</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Wei, Y., Huang, M. and Jiang, L. (2024) Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications. <italic>Catalysts</italic>, 14, Article 787. https://doi.org/10.3390/catal14110787 <pub-id pub-id-type="doi">10.3390/catal14110787</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/catal14110787">https://doi.org/10.3390/catal14110787</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Wei, Y.</string-name>
              <string-name>Huang, M.</string-name>
              <string-name>Jiang, L.</string-name>
            </person-group>
            <year>2024</year>
            <article-title>Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications</article-title>
            <source>Catalysts</source>
            <volume>14</volume>
            <elocation-id>787</elocation-id>
            <pub-id pub-id-type="doi">10.3390/catal14110787</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Zhang, Z., Chen, Y., Deng, J., Jia, X., Zhou, J. and Lv, H. (2014) Solid Dispersion of Berberine-Phospholipid Complex/TPGS 1000/SiO <sub>2</sub>: Preparation, Characterization and <italic>in Vivo</italic> Studies. <italic>International Journal of Pharmaceutics</italic>, 465, 306-316. https://doi.org/10.1016/j.ijpharm.2014.01.023 <pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.01.023</pub-id><pub-id pub-id-type="pmid">24456672</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijpharm.2014.01.023">https://doi.org/10.1016/j.ijpharm.2014.01.023</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Zhang, Z.</string-name>
              <string-name>Chen, Y.</string-name>
              <string-name>Deng, J.</string-name>
              <string-name>Jia, X.</string-name>
              <string-name>Zhou, J.</string-name>
              <string-name>Lv, H.</string-name>
              <string-name>Preparation, C</string-name>
            </person-group>
            <year>2014</year>
            <article-title>Solid Dispersion of Berberine-Phospholipid Complex/TPGS 1000/SiO2: Preparation, Characterization and in Vivo Studies</article-title>
            <source>International Journal of Pharmaceutics</source>
            <volume>465</volume>
            <pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.01.023</pub-id>
            <pub-id pub-id-type="pmid">24456672</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Mohapatra, N., Singh, T.G., Kumar, M. and Awasthi, A. (2026) A Comprehensive Compendium of Berberine: Sources, Chemistry, and Pharmacological Activities. <italic>Journal of the Science of Food and Agriculture</italic>, 106, 5142-5162. https://doi.org/10.1002/jsfa.70394 <pub-id pub-id-type="doi">10.1002/jsfa.70394</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jsfa.70394">https://doi.org/10.1002/jsfa.70394</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Mohapatra, N.</string-name>
              <string-name>Singh, T.G.</string-name>
              <string-name>Kumar, M.</string-name>
              <string-name>Awasthi, A.</string-name>
              <string-name>Sources, C</string-name>
            </person-group>
            <year>2026</year>
            <article-title>A Comprehensive Compendium of Berberine: Sources, Chemistry, and Pharmacological Activities</article-title>
            <source>Journal of the Science of Food and Agriculture</source>
            <volume>106</volume>
            <pub-id pub-id-type="doi">10.1002/jsfa.70394</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Mwene-Mbeja, T.M., Dufour, A., Lecka, J., Kaur, B.S. and Vaneeckhaute, C. (2020) Enzymatic Reactions in the Production of Biomethane from Organic Waste. <italic>Enzyme and Microbial Technology</italic>, 132, Article 109410. https://doi.org/10.1016/j.enzmictec.2019.109410 <pub-id pub-id-type="doi">10.1016/j.enzmictec.2019.109410</pub-id><pub-id pub-id-type="pmid">31731967</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.enzmictec.2019.109410">https://doi.org/10.1016/j.enzmictec.2019.109410</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Mwene-Mbeja, T.M.</string-name>
              <string-name>Dufour, A.</string-name>
              <string-name>Lecka, J.</string-name>
              <string-name>Kaur, B.S.</string-name>
              <string-name>Vaneeckhaute, C.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Enzymatic Reactions in the Production of Biomethane from Organic Waste</article-title>
            <source>Enzyme and Microbial Technology</source>
            <volume>132</volume>
            <elocation-id>109410</elocation-id>
            <pub-id pub-id-type="doi">10.1016/j.enzmictec.2019.109410</pub-id>
            <pub-id pub-id-type="pmid">31731967</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Zhu, P., Li, M., Yan, C., Sun, J., Peng, M., Huang, Z., <italic>et al</italic>. (2020) Aspirin Causes Lipid Accumulation and Damage to Cell Membrane by Regulating DCI1/OLE1 in <italic>Saccharomyces</italic><italic>cerevisiae</italic>. <italic>Microbial Drug Resistance</italic>, 26, 857-868. https://doi.org/10.1089/mdr.2019.0200 <pub-id pub-id-type="doi">10.1089/mdr.2019.0200</pub-id><pub-id pub-id-type="pmid">32049589</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/mdr.2019.0200">https://doi.org/10.1089/mdr.2019.0200</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Zhu, P.</string-name>
              <string-name>Li, M.</string-name>
              <string-name>Yan, C.</string-name>
              <string-name>Sun, J.</string-name>
              <string-name>Peng, M.</string-name>
              <string-name>Huang, Z.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Aspirin Causes Lipid Accumulation and Damage to Cell Membrane by Regulating DCI1/OLE1 in Saccharomyces cerevisiae</article-title>
            <source>Microbial Drug Resistance</source>
            <volume>26</volume>
            <pub-id pub-id-type="doi">10.1089/mdr.2019.0200</pub-id>
            <pub-id pub-id-type="pmid">32049589</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Alsop, R.J., Toppozini, L., Marquardt, D., Kučerka, N., Harroun, T.A. and Rheinstädter, M.C. (2015) Aspirin Inhibits Formation of Cholesterol Rafts in Fluid Lipid Membranes. <italic>Biochimica</italic><italic>et</italic><italic>Biophysica Acta</italic>— <italic>Biomembranes</italic>, 1848, 805-812. https://doi.org/10.1016/j.bbamem.2014.11.023 <pub-id pub-id-type="doi">10.1016/j.bbamem.2014.11.023</pub-id><pub-id pub-id-type="pmid">25475646</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbamem.2014.11.023">https://doi.org/10.1016/j.bbamem.2014.11.023</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Alsop, R.J.</string-name>
              <string-name>Toppozini, L.</string-name>
              <string-name>Marquardt, D.</string-name>
              <string-name>Harroun, T.A.</string-name>
            </person-group>
            <year>2015</year>
            <article-title>Aspirin Inhibits Formation of Cholesterol Rafts in Fluid Lipid Membranes</article-title>
            <source>Biochimica et Biophysica Acta—Biomembranes</source>
            <volume>1848</volume>
            <pub-id pub-id-type="doi">10.1016/j.bbamem.2014.11.023</pub-id>
            <pub-id pub-id-type="pmid">25475646</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Krmic, M., Perez, E., Scollan, P., Ivanchenko, K., Gamez Hernandez, A., Giancaspro, J., <italic>et al</italic>. (2023) Aspirin Interacts with Cholesterol-Containing Membranes in a pH-Dependent Manner. <italic>Langmuir</italic>, 39, 16444-16456. https://doi.org/10.1021/acs.langmuir.3c02242 <pub-id pub-id-type="doi">10.1021/acs.langmuir.3c02242</pub-id><pub-id pub-id-type="pmid">37939382</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/acs.langmuir.3c02242">https://doi.org/10.1021/acs.langmuir.3c02242</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Krmic, M.</string-name>
              <string-name>Perez, E.</string-name>
              <string-name>Scollan, P.</string-name>
              <string-name>Ivanchenko, K.</string-name>
              <string-name>Hernandez, A.</string-name>
              <string-name>Giancaspro, J.</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Aspirin Interacts with Cholesterol-Containing Membranes in a pH-Dependent Manner</article-title>
            <source>Langmuir</source>
            <volume>39</volume>
            <pub-id pub-id-type="doi">10.1021/acs.langmuir.3c02242</pub-id>
            <pub-id pub-id-type="pmid">37939382</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Visagie, J.L., Aruwajoye, G.S. and van der Sluis, R. (2024) Pharmacokinetics of Aspirin: Evaluating Shortcomings in the Literature. <italic>Expert Opinion on Drug Metabolism &amp; Toxicology</italic>, 20, 727-740. https://doi.org/10.1080/17425255.2024.2386368 <pub-id pub-id-type="doi">10.1080/17425255.2024.2386368</pub-id><pub-id pub-id-type="pmid">39092921</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/17425255.2024.2386368">https://doi.org/10.1080/17425255.2024.2386368</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Visagie, J.L.</string-name>
              <string-name>Aruwajoye, G.S.</string-name>
              <string-name>Sluis, R.</string-name>
            </person-group>
            <year>2024</year>
            <article-title>Pharmacokinetics of Aspirin: Evaluating Shortcomings in the Literature</article-title>
            <source>Expert Opinion on Drug Metabolism &amp; Toxicology</source>
            <volume>20</volume>
            <pub-id pub-id-type="doi">10.1080/17425255.2024.2386368</pub-id>
            <pub-id pub-id-type="pmid">39092921</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Knobloch, J., Suhendro, D.K., Zieleniecki, J.L., Shapter, J.G. and Köper, I. (2015) Membrane-Drug Interactions Studied Using Model Membrane Systems. <italic>Saudi Journal of Biological Sciences</italic>, 22, 714-718. https://doi.org/10.1016/j.sjbs.2015.03.007 <pub-id pub-id-type="doi">10.1016/j.sjbs.2015.03.007</pub-id><pub-id pub-id-type="pmid">26586998</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.sjbs.2015.03.007">https://doi.org/10.1016/j.sjbs.2015.03.007</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Knobloch, J.</string-name>
              <string-name>Suhendro, D.K.</string-name>
              <string-name>Zieleniecki, J.L.</string-name>
              <string-name>Shapter, J.G.</string-name>
            </person-group>
            <year>2015</year>
            <article-title>Membrane-Drug Interactions Studied Using Model Membrane Systems</article-title>
            <source>Saudi Journal of Biological Sciences</source>
            <volume>22</volume>
            <pub-id pub-id-type="doi">10.1016/j.sjbs.2015.03.007</pub-id>
            <pub-id pub-id-type="pmid">26586998</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Lucio, M., Lima, J.L.F.C. and Reis, S. (2010) Drug-Membrane Interactions: Significance for Medicinal Chemistry. <italic>Current Medicinal Chemistry</italic>, 17, 1795-1809. https://doi.org/10.2174/092986710791111233 <pub-id pub-id-type="doi">10.2174/092986710791111233</pub-id><pub-id pub-id-type="pmid">20345343</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/092986710791111233">https://doi.org/10.2174/092986710791111233</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Lucio, M.</string-name>
              <string-name>Lima, J.L.F.C.</string-name>
              <string-name>Reis, S.</string-name>
            </person-group>
            <year>2010</year>
            <article-title>Drug-Membrane Interactions: Significance for Medicinal Chemistry</article-title>
            <source>Current Medicinal Chemistry</source>
            <volume>17</volume>
            <pub-id pub-id-type="doi">10.2174/092986710791111233</pub-id>
            <pub-id pub-id-type="pmid">20345343</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Lysenko, V., Gao, M.L., Sterk, F.A.C., Innocenti, P., Slingerland, C.J. and Martin, N.I. (2025) Design, Synthesis, and Antibacterial Evaluation of Rifampicin-Siderophore Conjugates. <italic>ACS</italic><italic>Infectious</italic><italic>Diseases</italic>, 11, 2301-2309. https://doi.org/10.1021/acsinfecdis.5c00311 <pub-id pub-id-type="doi">10.1021/acsinfecdis.5c00311</pub-id><pub-id pub-id-type="pmid">40616779</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/acsinfecdis.5c00311">https://doi.org/10.1021/acsinfecdis.5c00311</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Lysenko, V.</string-name>
              <string-name>Gao, M.L.</string-name>
              <string-name>Sterk, F.A.C.</string-name>
              <string-name>Innocenti, P.</string-name>
              <string-name>Slingerland, C.J.</string-name>
              <string-name>Martin, N.I.</string-name>
              <string-name>Design, S</string-name>
            </person-group>
            <year>2025</year>
            <article-title>Design, Synthesis, and Antibacterial Evaluation of Rifampicin-Siderophore Conjugates</article-title>
            <source>ACS Infectious Diseases</source>
            <volume>11</volume>
            <pub-id pub-id-type="doi">10.1021/acsinfecdis.5c00311</pub-id>
            <pub-id pub-id-type="pmid">40616779</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Le-Deygen, I.M., Safronova, A.S., Mamaeva, P.V., Kolmogorov, I.M., Skuredina, A.A. and Kudryashova, E.V. (2022) Drug-Membrane Interaction as Revealed by Spectroscopic Methods: The Role of Drug Structure in the Example of Rifampicin, Levofloxacin and Rapamycin. <italic>Biophysica</italic>, 2, 353-365. https://doi.org/10.3390/biophysica2040032 <pub-id pub-id-type="doi">10.3390/biophysica2040032</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/biophysica2040032">https://doi.org/10.3390/biophysica2040032</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Le-Deygen, I.M.</string-name>
              <string-name>Safronova, A.S.</string-name>
              <string-name>Mamaeva, P.V.</string-name>
              <string-name>Kolmogorov, I.M.</string-name>
              <string-name>Skuredina, A.A.</string-name>
              <string-name>Kudryashova, E.V.</string-name>
              <string-name>Rifampicin, L</string-name>
            </person-group>
            <year>2022</year>
            <article-title>Drug-Membrane Interaction as Revealed by Spectroscopic Methods: The Role of Drug Structure in the Example of Rifampicin, Levofloxacin and Rapamycin</article-title>
            <source>Biophysica</source>
            <volume>2</volume>
            <pub-id pub-id-type="doi">10.3390/biophysica2040032</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Singh, C., Bhatt, T.D., Gill, M.S. and Suresh, S. (2014) Novel Rifampicin-Phospholipid Complex for Tubercular Therapy: Synthesis, Physicochemical Characterization and In-Vivo Evaluation. <italic>International Journal of Pharmaceutics</italic>, 460, 220-227. https://doi.org/10.1016/j.ijpharm.2013.10.043 <pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.10.043</pub-id><pub-id pub-id-type="pmid">24188983</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijpharm.2013.10.043">https://doi.org/10.1016/j.ijpharm.2013.10.043</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Singh, C.</string-name>
              <string-name>Bhatt, T.D.</string-name>
              <string-name>Gill, M.S.</string-name>
              <string-name>Suresh, S.</string-name>
              <string-name>Synthesis, P</string-name>
            </person-group>
            <year>2014</year>
            <article-title>Novel Rifampicin-Phospholipid Complex for Tubercular Therapy: Synthesis, Physicochemical Characterization and In-Vivo Evaluation</article-title>
            <source>International Journal of Pharmaceutics</source>
            <volume>460</volume>
            <pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.10.043</pub-id>
            <pub-id pub-id-type="pmid">24188983</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Santos, R.M.S., Samelo, J., Oliveira, A.C., Cordeiro, M.M., Mora, M.J., Granero, G.E., <italic>et al</italic>. (2025) Interaction of the Antibiotic Rifampicin with Lipid Membranes. <italic>Biomolecules</italic>, 15, Article 320. https://doi.org/10.3390/biom15030320 <pub-id pub-id-type="doi">10.3390/biom15030320</pub-id><pub-id pub-id-type="pmid">40149856</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/biom15030320">https://doi.org/10.3390/biom15030320</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Santos, R.M.S.</string-name>
              <string-name>Samelo, J.</string-name>
              <string-name>Oliveira, A.C.</string-name>
              <string-name>Cordeiro, M.M.</string-name>
              <string-name>Mora, M.J.</string-name>
              <string-name>Granero, G.E.</string-name>
            </person-group>
            <year>2025</year>
            <article-title>Interaction of the Antibiotic Rifampicin with Lipid Membranes</article-title>
            <source>Biomolecules</source>
            <volume>15</volume>
            <elocation-id>320</elocation-id>
            <pub-id pub-id-type="doi">10.3390/biom15030320</pub-id>
            <pub-id pub-id-type="pmid">40149856</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Kubala, M., Teisinger, J., Ettrich, R., Hofbauerová, K., Kopecký, V., Baumruk, V., <italic>et</italic><italic>al</italic>. (2003) Eight Amino Acids Form the ATP Recognition Site of Na <sup>+</sup>/K <sup>+</sup>-ATPase. <italic>Biochemistry</italic>, 42, 6446-6452. https://doi.org/10.1021/bi034162u <pub-id pub-id-type="doi">10.1021/bi034162u</pub-id><pub-id pub-id-type="pmid">12767226</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/bi034162u">https://doi.org/10.1021/bi034162u</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Kubala, M.</string-name>
              <string-name>Teisinger, J.</string-name>
              <string-name>Ettrich, R.</string-name>
              <string-name>Baumruk, V.</string-name>
            </person-group>
            <year>2003</year>
            <article-title>Eight Amino Acids Form the ATP Recognition Site of Na+/K+-ATPase</article-title>
            <source>Biochemistry</source>
            <volume>42</volume>
            <pub-id pub-id-type="doi">10.1021/bi034162u</pub-id>
            <pub-id pub-id-type="pmid">12767226</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Bisello, G., Rossignoli, G., Choi, S., Phillips, R.S. and Bertoldi, M. (2023) Active Site Serine-193 Modulates Activity of Human Aromatic Amino Acid Decarboxylase. <italic>Biochemical and Biophysical Research Communications</italic>, 679, 6-14. https://doi.org/10.1016/j.bbrc.2023.08.049 <pub-id pub-id-type="doi">10.1016/j.bbrc.2023.08.049</pub-id><pub-id pub-id-type="pmid">37651872</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbrc.2023.08.049">https://doi.org/10.1016/j.bbrc.2023.08.049</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Bisello, G.</string-name>
              <string-name>Rossignoli, G.</string-name>
              <string-name>Choi, S.</string-name>
              <string-name>Phillips, R.S.</string-name>
              <string-name>Bertoldi, M.</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Active Site Serine-193 Modulates Activity of Human Aromatic Amino Acid Decarboxylase</article-title>
            <source>Biochemical and Biophysical Research Communications</source>
            <volume>679</volume>
            <pub-id pub-id-type="doi">10.1016/j.bbrc.2023.08.049</pub-id>
            <pub-id pub-id-type="pmid">37651872</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Li, T., Huo, L., Pulley, C. and Liu, A. (2012) Decarboxylation Mechanisms in Biological System. <italic>Bioorganic Chemistry</italic>, 43, 2-14. https://doi.org/10.1016/j.bioorg.2012.03.001 <pub-id pub-id-type="doi">10.1016/j.bioorg.2012.03.001</pub-id><pub-id pub-id-type="pmid">22534166</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bioorg.2012.03.001">https://doi.org/10.1016/j.bioorg.2012.03.001</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Li, T.</string-name>
              <string-name>Huo, L.</string-name>
              <string-name>Pulley, C.</string-name>
              <string-name>Liu, A.</string-name>
            </person-group>
            <year>2012</year>
            <article-title>Decarboxylation Mechanisms in Biological System</article-title>
            <source>Bioorganic Chemistry</source>
            <volume>43</volume>
            <pub-id pub-id-type="doi">10.1016/j.bioorg.2012.03.001</pub-id>
            <pub-id pub-id-type="pmid">22534166</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>